LIFE bioCEEd has led the seed investment round in BreathPredict Ltd, a United Kingdom-based medical technology company developing Exhale-Dx™, an AI-powered handheld diagnostic device designed to diagnose asthma in under one minute. The round was joined by Bethnal Green Ventures (BGV), one of the United Kingdom's leading early-stage technology investors and an existing shareholder in the company.

The technology combines advanced breath-analysis sensors with proprietary artificial intelligence algorithms to provide rapid, non-invasive, point-of-care diagnostics using only relaxed tidal breathing. In pilot clinical studies, Exhale-Dx™ demonstrated diagnostic accuracy of 93% while also showing the ability to identify physiological changes associated with asthma exacerbations up to three days in advance.

Asthma affects more than 262 million people globally and remains one of the most common chronic respiratory diseases worldwide. Despite this burden, current diagnostic methods remain heavily reliant on spirometry and other tools that can be difficult to use in primary care settings, particularly among children and elderly patients.

As lead investor, LIFE bioCEEd will support BreathPredict through its next phase of development, including multi-centre clinical validation and regulatory certification activities required for commercial deployment within the European Union and United Kingdom. The participation of Bethnal Green Ventures in the round further reinforces confidence in both the technology and the company's future development trajectory.

The investment represents LIFE bioCEEd's first transaction in the United Kingdom and further strengthens the company's growing portfolio of innovative biomedical technologies spanning diagnostics, therapeutics, gene therapy, and medical devices across Europe.

"We believe BreathPredict has the potential to fundamentally improve how asthma is diagnosed and monitored in routine clinical practice. We are excited to support the company through the next stage of clinical and regulatory development," said Stefan Savić, CEO of LIFE bioCEEd.